Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Which Came First? Alogliptin Avoids Possible Exclusivity Dispute

This article was originally published in RPM Report

Executive Summary

An unusual footnote in FDA’s approval letter for Takeda’s long-delayed diabetes medicine means that the company won’t have to worry about losing five-year exclusivity on the molecule.

You may also be interested in...

NCE Market Exclusivity: Eisai Targets DEA Scheduling Delays, Pozen Pushes Bill For Combo Products

Eisai citizen petition requests Belviq and Fycompa approval dates coincide with final DEA scheduling; Pozen advocates exclusivity for new combinations of previously approved molecules.

Much “Ado” About Biosimilars

The approval of Kadcyla gives Roche/Genentech yet another new breakthrough cancer therapy in the US. It also offers some clues about the future of biosimilars at FDA.

Takeda’s Hat Trick Marks The First New Molecular Entity Of 2013

Takeda’s type 2 diabetes drug alogliptin – on its third pass through FDA – was cleared Jan. 25 as a single agent as Nesina, in combination with metformin as Kazano and in combination with pioglitazone as Oseni.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts